Product Name:
JAK3-2
Product Number:
ab-nk086-3
Target Full Name: Janus protein-tyrosine kinase 3
Target Alias: JAK-3; JAK3_HUMAN; JAKL; Janus kinase 3; Kinase JAK3; Leukocyte janus kinase; LJAK; L-JAK; CCDS12366.1; ENSG00000105639
Product Type Specific: JAK3 protein kinase pan-specific antibody
Antibody Code: NK086-3
Antibody Target Type: Pan-specific
Protein UniProt: P52333
Protein SigNET: JAK3
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human JAK3 sequence peptide Cat. No.: PE-01AUQ90
Antibody Immunogen Sequence: CDRPSFSALGPQLDML
Antibody Immunogen Description: Corresponds to amino acid residues D1084 to L1098; Kinase last alpha-chain.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 1 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity with recombinant human JAK3 on protein dot blots.
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Rhesus Macaque.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 110-125 kDa.
Antibody Specificity: Medium
Antibody Cross Reactivity: No immunoreactivity on protein dot blots with recombinant human JAK1, JAK2, and Tyk2.
Related Product 1: JAK3 (1084-1098) antibody blocking peptide (Cat. No.: PE-01AUQ90)
Related Product 2: JAK3Selectide kinase substrate peptide (Cat. No.: PE-01BHS95)
Related Product 3: JAK2Selectide kinase substrate peptide (Cat. No.: PE-01BHR90)
Related Product 4: IRS1 (891-902) KinSub kinase substrate peptide (Cat. No.: PE-01AQD95)
Related Product 5: JAK3 expression antibody (Cat. No.: AB-NK086-2)
Related Product 6: JAK3 expression antibody (Cat. No.: AB-NK086-4)
Related Product 7: JAK3 Y980+Y981 phosphorylation antibody (Cat. No.: AB-PK669)
Related Product 8: JAK3 Y785 phosphorylation antibody (Cat. No.: AB-PK934)
Related Product 9: JAK1 expression antibody (Cat. No.: AB-NK084-3)
Related Product 10: JAK2 expression antibody (Cat. No.: AB-NK085-2)
Scientific Background: JAK3 is a protein-tyrosine kinase of the TK group and JAKA family, and acts as a crucial transducer of cytokine signals through the common gamma chain of interleukin receptor complexes (IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21). It features specialized domains, including a FERM domain (for receptor binding) and a C-terminal active PTK domain (for tyrosine kinase activity), and a pseudokinase domain .Phosphorylation at Thr-8, Tyr-904 and Tyr-980 increases phosphotransferase activity. Phosphorylation at Tyr-939 also increases phosphotransferase activity and induces interaction with STAT5A. Phosphorylation at Tyr-785 induces interaction with SH2-B-beta. Phosphorylation at Tyr-981 inhibits phosphotransferase activity. It is involved in cytokine receptor-mediated intracellular signal transduction, including activation of PI3K. It is primarily restricted to hematopoietic cells, unlike JAK1/JAK2/TYK2, which are found in almost all tissues. Inactivating mutations in JAk3 cause autosomal recessive JAK3-deficient severe combined immunodeficiency (SCID). It may be an oncoprotein (OP). JAK3 mutations were commonly found in juvenile myelomonocytic leukemia from whole-exome sequencing studies from 13 individuals. JAK3 were hypothesized to be involved in the progression rather than the initiation of leukemia, and patients with mutated JAK3 were associated with poorer clinical results. Overactivation or gain-of-function mutations are linked to hematological malignancies, including acute megakaryoblastic leukemia (AMKL) and cutaneous T cell lymphoma (CTCL). Mutations in this gene have also been found in mouth, and ovarian cancers. This description may include information annotated by UniProt and/or Google AI.